RU2348617C2 - Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение - Google Patents

Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение Download PDF

Info

Publication number
RU2348617C2
RU2348617C2 RU2006112427/04A RU2006112427A RU2348617C2 RU 2348617 C2 RU2348617 C2 RU 2348617C2 RU 2006112427/04 A RU2006112427/04 A RU 2006112427/04A RU 2006112427 A RU2006112427 A RU 2006112427A RU 2348617 C2 RU2348617 C2 RU 2348617C2
Authority
RU
Russia
Prior art keywords
alkyl
optionally further
independently selected
further substituted
alkoxy
Prior art date
Application number
RU2006112427/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2006112427A (ru
Inventor
Петер ХАНСЕН (SE)
Петер Хансен
Каролина ЛАВИТЦ (SE)
Каролина ЛАВИТЦ
Ханс ЛЁНН (SE)
Ханс Лённ
Антониос НИКИТИДИС (SE)
Антониос Никитидис
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29212489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2348617(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2006112427A publication Critical patent/RU2006112427A/ru
Application granted granted Critical
Publication of RU2348617C2 publication Critical patent/RU2348617C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • C07D213/85Nitriles in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
RU2006112427/04A 2003-09-18 2004-09-15 Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение RU2348617C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0302487A SE0302487D0 (sv) 2003-09-18 2003-09-18 Novel compounds
SE0302487-4 2003-09-18

Publications (2)

Publication Number Publication Date
RU2006112427A RU2006112427A (ru) 2007-11-10
RU2348617C2 true RU2348617C2 (ru) 2009-03-10

Family

ID=29212489

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006112427/04A RU2348617C2 (ru) 2003-09-18 2004-09-15 Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение

Country Status (25)

Country Link
US (1) US20070043036A1 (https=)
EP (1) EP1663974B1 (https=)
JP (1) JP2007505902A (https=)
KR (1) KR20060096995A (https=)
CN (1) CN100439339C (https=)
AR (1) AR046083A1 (https=)
AT (1) ATE420861T1 (https=)
AU (1) AU2004272485B2 (https=)
BR (1) BRPI0414570A (https=)
CA (1) CA2538410A1 (https=)
CO (1) CO5670357A2 (https=)
DE (1) DE602004019110D1 (https=)
ES (1) ES2319300T3 (https=)
IL (1) IL173986A0 (https=)
IS (1) IS8394A (https=)
MX (1) MXPA06002723A (https=)
NO (1) NO20061700L (https=)
RU (1) RU2348617C2 (https=)
SA (1) SA04250300B1 (https=)
SE (1) SE0302487D0 (https=)
TW (1) TW200526579A (https=)
UA (1) UA84878C2 (https=)
UY (1) UY28513A1 (https=)
WO (1) WO2005026124A1 (https=)
ZA (1) ZA200602262B (https=)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
TW200700392A (en) * 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
ES2524922T3 (es) 2005-05-10 2014-12-15 Intermune, Inc. Derivados de piridona para modular el sistema de proteína cinasa activada por estrés
BRPI0614290A2 (pt) 2005-08-08 2011-03-22 Argenta Discovery Ltd derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
US20070104699A1 (en) * 2005-09-29 2007-05-10 University Of Alberta Compositions for and methods of granzyme B inhibition
GB0605469D0 (en) * 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
EP2077262A4 (en) 2006-10-23 2011-12-28 Takeda Pharmaceutical IMINOPYRIDINE DERIVATIVE AND USE THEREOF
US7851489B2 (en) 2006-11-08 2010-12-14 Bristol-Myers Squibb Company Pyridinone compounds
WO2009061271A1 (en) 2007-11-06 2009-05-14 Astrazeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
PT2229358E (pt) 2007-12-14 2011-06-29 Pulmagen Therapeutics Asthma Ltd Indoles e sua utilização terapêutica
EA017736B1 (ru) 2008-01-23 2013-02-28 Бристол-Маерс Сквибб Компани Соединения 4-пиридинона и их применение для лечения рака
US8481569B2 (en) 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
SG174134A1 (en) 2009-02-17 2011-10-28 Chiesi Farma Spa Triazolopyridine derivatives as p38 map kinase inhibitors
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
CA2773618A1 (en) * 2009-10-02 2011-04-07 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
CA2782384A1 (en) * 2009-12-08 2011-06-16 Boehringer Ingelheim International Gmbh Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
CN104024241B (zh) 2011-08-01 2016-01-20 大日本住友制药株式会社 尿嘧啶衍生物和其用于医学目的的用途
BR112014013178A2 (pt) 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
DK2788349T3 (en) 2011-12-09 2017-01-30 Chiesi Farm Spa kinase inhibitors
KR20140105459A (ko) 2011-12-09 2014-09-01 키에시 파르마슈티시 엣스. 피. 에이. 키나아제 억제제
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2015151886A (ru) 2013-06-06 2017-06-08 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Ингибиторы киназ
US9221807B2 (en) 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
HK1249504A1 (zh) 2015-09-02 2018-11-02 Glaxosmithkline Intellectual Property (No. 2) Limited 用作溴结构域抑制剂的吡啶酮二甲酰胺
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
EP3394058B1 (en) 2015-12-23 2020-10-14 Chiesi Farmaceutici S.p.A. N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
EP3394059B1 (en) 2015-12-23 2020-11-25 Chiesi Farmaceutici S.p.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
AR107164A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa INHIBIDORES DE QUINASA p38
JP7034942B2 (ja) 2016-05-05 2022-03-14 エフ.ホフマン-ラ ロシュ アーゲー ピラゾール誘導体、その組成物及び治療的使用
CN109890817B (zh) 2016-09-06 2022-06-17 豪夫迈·罗氏有限公司 8-(氮杂环丁烷-1-基)-[1,2,4]三唑并[1,5-a]吡啶基化合物、其组合物和应用方法
EP3562809B1 (en) 2016-12-29 2021-06-09 F. Hoffmann-La Roche AG Pyrazolopyrimidine compounds and methods of use thereof
CN110494434B (zh) 2017-03-14 2022-05-24 豪夫迈·罗氏有限公司 吡唑并氯苯基化合物、其组合物及其使用方法
CN110678467B (zh) 2017-05-22 2023-06-13 豪夫迈·罗氏有限公司 治疗化合物和组合物及其使用方法
WO2018215389A1 (en) 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
EP3740488A1 (en) 2018-01-15 2020-11-25 F. Hoffmann-La Roche AG Pyrazolopyrimidine compounds as jak inhibitors
EP3749697A4 (en) 2018-02-05 2021-11-03 Bio-Rad Laboratories, Inc. CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE
CN110192948B (zh) * 2019-05-28 2022-01-04 河南省超亚医药器械有限公司 一种小儿腹部热敷贴
CN110192947B (zh) * 2019-05-28 2022-01-04 河南省超亚医药器械有限公司 一种小儿肺部热敷贴
US20200399274A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
CA3140024A1 (en) 2019-06-18 2020-12-24 Mark Edward Zak Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof
WO2020257143A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
CN114650819A (zh) 2019-09-17 2022-06-21 美莱奥生物制药第四有限公司 用于治疗移植物排斥、闭塞性细支气管炎综合征和移植物抗宿主病的阿维来司他
WO2021209740A1 (en) 2020-04-16 2021-10-21 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
EP4419102A1 (en) 2021-10-20 2024-08-28 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis
CN114057630B (zh) * 2021-12-23 2023-06-02 郑州大学 吡非尼酮衍生物及其合成方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521179A (en) * 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
RU2067579C1 (ru) * 1994-10-07 1996-10-10 Пермский фармацевтический институт 3-(2'-нафтоилметилен)-пиперазинон-2 и 1-n-фенил-3-фенацилиденпиперазинон-2, проявляющие противовоспалительную активность
RU96113098A (ru) * 1993-11-19 1998-09-27 Парк, Дэвис энд Компани Производные 5,6-дигидропирона в качестве ингибитора протеазы и антивирусные средства
RU2124004C1 (ru) * 1992-02-07 1998-12-27 Руссель-Юклаф Производные пиридона, способ их получения и фармацевтическая композиция на их основе
WO2002053543A1 (en) * 2000-12-28 2002-07-11 Shionogi & Co., Ltd. Pyridone derivative having affinity for cannabinoid 2-type receptor
GB2383326A (en) * 2001-12-20 2003-06-25 Bayer Ag Antiinflammatory dihydropyridines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207145D0 (en) * 1991-04-18 1992-05-13 Ici Plc Heterocyclic amides
DE69433705T2 (de) * 1993-11-19 2005-03-10 Parke, Davis & Company 5,6-Dihydropyronderivate als Proteaseinhibitoren und Antiviralmittel
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
DE60214428T2 (de) * 2001-12-20 2007-09-20 Bayer Healthcare Ag 1, 4-dihydro-1, 4-diphenylpyridin-derivate
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521179A (en) * 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
RU2124004C1 (ru) * 1992-02-07 1998-12-27 Руссель-Юклаф Производные пиридона, способ их получения и фармацевтическая композиция на их основе
RU96113098A (ru) * 1993-11-19 1998-09-27 Парк, Дэвис энд Компани Производные 5,6-дигидропирона в качестве ингибитора протеазы и антивирусные средства
RU2067579C1 (ru) * 1994-10-07 1996-10-10 Пермский фармацевтический институт 3-(2'-нафтоилметилен)-пиперазинон-2 и 1-n-фенил-3-фенацилиденпиперазинон-2, проявляющие противовоспалительную активность
WO2002053543A1 (en) * 2000-12-28 2002-07-11 Shionogi & Co., Ltd. Pyridone derivative having affinity for cannabinoid 2-type receptor
GB2383326A (en) * 2001-12-20 2003-06-25 Bayer Ag Antiinflammatory dihydropyridines

Also Published As

Publication number Publication date
IL173986A0 (en) 2006-07-05
RU2006112427A (ru) 2007-11-10
ES2319300T3 (es) 2009-05-06
ZA200602262B (en) 2007-07-25
EP1663974B1 (en) 2009-01-14
CN1856467A (zh) 2006-11-01
CA2538410A1 (en) 2005-03-24
DE602004019110D1 (de) 2009-03-05
AR046083A1 (es) 2005-11-23
SE0302487D0 (sv) 2003-09-18
NO20061700L (no) 2006-04-18
SA04250300B1 (ar) 2008-09-07
UA84878C2 (ru) 2008-12-10
UY28513A1 (es) 2005-04-29
ATE420861T1 (de) 2009-01-15
KR20060096995A (ko) 2006-09-13
IS8394A (is) 2006-03-31
CN100439339C (zh) 2008-12-03
AU2004272485B2 (en) 2008-03-13
EP1663974A1 (en) 2006-06-07
WO2005026124A1 (en) 2005-03-24
MXPA06002723A (es) 2006-06-06
US20070043036A1 (en) 2007-02-22
AU2004272485A1 (en) 2005-03-24
TW200526579A (en) 2005-08-16
CO5670357A2 (es) 2006-08-31
BRPI0414570A (pt) 2006-11-07
HK1089167A1 (en) 2006-11-24
JP2007505902A (ja) 2007-03-15

Similar Documents

Publication Publication Date Title
RU2348617C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
RU2328486C2 (ru) Производные 2-пиридона в качестве ингибиторов нейтрофильной эластазы
RU2353616C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
RU2500680C2 (ru) Новые замещенные пиридин-2-оны и пиридазин-3-оны
PE20230238A1 (es) Inhibidores de kras g12c
RU2350605C2 (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
RU2336275C2 (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью, и фармацевтическая композиция
RU2403251C2 (ru) Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70
RU2395500C2 (ru) 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
RU2363700C2 (ru) Производные хинуклидина и фармацевтические композиции, содержащие их
PE20220133A1 (es) Inhibidores del inflamasoma nlrp3
BR112022012641A2 (pt) Compostos tricíclicos substituídos
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
EA200401613A1 (ru) Лекарственное средство для лечения рака
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR037329A1 (es) Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
EA017806B1 (ru) Антимикробные соединения, их синтез и применение для лечения инфекций у млекопитающих
EA200401615A1 (ru) ИНГИБИТОРЫ АКТИВАЦИИ NF-kB
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
CY1111980T1 (el) Παραγωγα του αμιδιου τα οποια φερουν ενα υποκαταστατο του κυκλοπροπυλαμινοκαρβονυλιου και χρησιμευουν ως αναστολεις κυτταροκινης
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
KR950702554A (ko) 소염제로서 유용한 2-헤테로시클릭-5-히드록시-1,3-피리미딘 (2-Heterocyclic-5-Hydroxy-1,3-Pyrimidines Useful as Antiinflammatory Agents)
BRPI0409374A (pt) composto, composição farmacêutica, uso de pelo menos um composto, e, método para o tratamento de um distúrbio médico

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20090916